Geisinger Research

🗣️Don't miss the April 13th #MyCode Genomic Screening and Counseling Program Grand Rounds "Hereditary Paraganglioma and Pheochromocytoma Management in the #MyCode Population" Presented by: Alyson Floyd, MS, CGC & Brian C. Jameson, DO 🕛12:00-1:00 PM

Today we honor the strength of the #RareDisease community and the science helping to rewrite the diagnostic journey.💫🩵

Our genomic-first approach has revealed rare genetic disorders much earlier than traditional methods, offering hope for faster diagnosis and targeted care. Rare doesn’t mean you are alone!

Today is #RareDiseaseDay2026. Millions around the world live with conditions that are often undiagnosed or overlooked. At Geisinger, researchers use cutting-edge genomic science to change that.🔬

Presented by: Megan Roberts, PhD, Associate Professor and Interim Vice Chair, Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, @UNC 🗓️March 9th 🕛12:00-1:00 PM ET

🚨Check out the next #MyCode Genomic Screening and Counseling Program Grand Rounds "Facilitating the Implementation of Population-wide Genomic Screening across Diverse Populations and Settings"

Health: Screening is the first step, but it must be paired with robust clinical interventions to ensure that "detected" quickly becomes "treated." Still much work needed to streamline path from an abnormal kidney home test to optimal guideline-recommended treatment - let go!

📱 Smartphone Testing: A Catalyst for Patient Activation in CKD shows that while technology can bridge the screening gap, it also highlights a critical opportunity for patient activation. Using smartphone-enabled home UACR testing, we didn't just see screening rates more than

prescriptions for ACEi, ARBs, and SGLT2 inhibitors. ⚠️ The "Last Mile" Challenge Despite these gains, the surge in screening didn't immediately translate to a population-level shift in medication usage. This underscores a vital truth in Population Health: Screening is the first

Of the patients who discussed their results with a provider, 83% of those interactions were initiated by the patient. Albuminuria detected in 38% of the hypertension group and 45% of the diabetes group. Among those with detected albuminuria, we saw a trend toward increased

Presented by: Kelly Morgan, MS, CGC, LeeAnn Pawlak, BS, & Brad Confer, DO 🗓️February 9th 🕛12:00-12:45 PM ET

🗣️Join the next #MyCode Genomic Screening and Counseling Program Grand Rounds "Evaluating the Impact of Multidisciplinary Longitudinal Management for Patients with #LynchSyndrome: #Geisinger’s Experience with the Inherited Risk Gastrointestinal Clinic" 👇

Together, studies like these can help clinicians better recognize risk, ask informed exposure questions, and tailor prevention and treatment. x.com/JCOCCI_ASCO/st…

A new @PSUResearch study connecting farming practices to melanoma adds to this evidence, reinforcing how agriculture shapes community health. ⬇️

Geisinger's Center for Community Environment and Health has long reported links between agricultural practices and health, from asthma exacerbations to infectious diseases. 🧵⬇️

The first #MyCode Genomic Screening and Counseling Program Grand Rounds of #NewYear2026 "MyCode Participant Genetic Risk- Beyond the Return List" Presented by: Cameron Hayes, MS-CGC, & Hannah Krammes, MS-CGC 🗓️January 12th 🕛12:00-12:45 PM

The next #MyCode Genomic Screening and Counseling Program Grand Rounds "Updates and Outcomes: Prospective Disclosure of Results Identified in Deceased MyCode Participants" Presenters: Gabrielle Shermanski, Kelly Morgan, & Deb Klinger 🗓️12/8 🕛12:00-12:45PM